Maxygen, Inc.

Roche Palo Alto LLC

Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Roche Glycart Ag

Genentech, Inc.

Hans Koll

Andreas Schaubmar

Phillip A Patten

Stefan Seeber

Stephan Fischer

Ralf Schumacher

Torben Lauesgaard Nissen

Anne Vogt

Harald Kropshofer

Kurt Lang

Bernd Bohrmann

Diana Schuhbauer

Pablo Umana

Mark X Sliwkowski

Joerg Thomas Regula

Birgit Bossenmaier

Sridhar Viswanathan

Manfred Brockhaus

Walter Huber

Hansruedi Loetscher

Karl Weyer

Peter Sondermann

Christiane Jaeger

Anne Zeck

Hans-joachim Müller

Stephen Michael Kelsey

Bianca Eser

Hans-Joachim Muller

Frank Wiegeshoff

This invention describes a new analytical method to determine the quantity and distribution of fucose per Fc within an antibody preparation.

A-fucosylation detection in antibodies

The present invention relates to a purified antibody molecule preparation being characterized in that at least one antigen binding site comprises a glycosylated asparagine (Asn) in the variable region of the heavy chain (V). More specifically, a pharmaceutical and a diagnostic composition comprising said antibody molecule and antibody mixtures are provided which is/are capable of specifically recognizing the &#x3b2;-A4 peptide/A&#x3b2;4. The present invention relates in particular to a mixture of antibodies comprising one or two glycosylated antigen binding sites with a glycosylated asparagine (Asn) in the variable region of the heavy chain, i.e. mixtures of isoforms of antibodies which comprise a glycosylated Asn in the variable region of the heavy chain (V). Also disclosed are compositions or antibody preparations comprising the specifically glycosylated antibody isoforms. Furthermore, the pharmaceutical and diagnostic uses for these antibodies are provided. The antibody isoforms may for example be used in the pharmaceutical intervention of amyloidogenesis or amyloid-plaque formation and/or in the diagnosis of the same.

Antibodies against amyloid beta 4 with glycosylation in the variable region

The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.

Interferon-alpha polypeptides and conjugates

Growing community of inventors

Oberroth, Germany

Hans Koll